300+ investors in your industry, stage, and region Get
Any industry
Google
Clean Energy
EdTech
Artificial Intelligence
Local
Enterprise Software
Travel
Platforms
InsurTech
Oil and Gas
Social Impact
Retail
Cryptocurrency
SaaS
Film
Restaurants
Photography
Payments
Email
CleanTech
Energy
Marketplace
Fitness
Organic Food
Machine Learning
Health Care
Agriculture (AgTech)
Gaming
Facebook
Social Network
Blockchain
B2B
Video Games
Big Data
Medical Device
Wellness
Mobile
Education
Automotive
Hospitality
Biotechnology
Sports
Consumer
Legal
eSports
Construction
Software
Renewable Energy
Crowdfunding
Venture Capital
Fashion
Social
Theatre
Beauty
Medical
Infrastructure
Recruiting
Cannabis
LGBT
Celebrity
Climate
Web3
Mobile Apps
Life Science
Wine and Spirits
Music
Food and Beverage
Publishing
Art
Manufacturing
Digital Media
FinTech
Finance
Financial Services
Real Estate
Social Media
Franchise
Mobile Advertising
Sporting Goods
Non Profit
Android
Internet
Sustainability
Hardware
Biotech
Impact
Enterprise
Proptech
Transportation
Community
Media (Entertainment)
Any country
Hong Kong
Thailand
United Arab Emirates
Egypt
Greece
Croatia
Burkina Faso
South Korea
Singapore
Gibraltar
Liberia
Taiwan
Tunisia
Sweden
Zimbabwe
Zambia
Norway
Tajikistan
Mexico
Nigeria
Russian Federation
Togo
Guinea
Nepal
Iran
Isle of Man
Madagascar
Pakistan
Romania
Brazil
Kyrgyzstan
LATAM
Africa
Oceania
Oman
Poland
Puerto Rico
Sudan
Cameroon
Guernsey
Andorra
Colombia
Armenia
China
Costa Rica
Czech Republic
Kenya
Kuwait
Marshall Islands
Luxembourg
Malta
Mozambique
Namibia
Mauritius
Nicaragua
Panama
Serbia
Uzbekistan
New Zealand
Australia
Saudi Arabia
Sri Lanka
Jamaica
Switzerland
Guatemala
Kazakhstan
Cayman Islands
Venezuela
Malawi
Myanmar
Uganda
Turkey
Uruguay
Moldova
Morocco
Seychelles
Paraguay
Botswana
Ireland
Japan
South Africa
France
Georgia
Denmark
Ghana
Iraq
Mali
Latvia
Malaysia
Portugal
Philippines
Sierra Leone
Rwanda
El Salvador
Senegal
Tanzania
Germany
India
United States
Indonesia
Middle East
Dominican Republic
Bermuda
Asia
Albania
Spain
Angola
Europe
Cyprus
Qatar
Argentina
Bangladesh
Belgium
Barbados
Jordan
Austria
Ethiopia
Azerbaijan
Bulgaria
Ecuador
Bahamas
Faroe Islands
Estonia
Jersey
Bahrain
Canada
Bolivia
Algeria
Belize
Finland
Italy
Belarus
Hungary
Grenada
Israel
United Kingdom
Iceland
Cambodia
Honduras
Lithuania
Liechtenstein
Lebanon
Mongolia
Peru
Slovenia
San Marino
Ukraine
Vietnam
Chile
Angel Investors
VC Funds
All Investors
Access Full Database - Free Forever
Open database
Delaware Crossing Investor Group, VC Fund

Delaware Crossing Investor Group

VC Fund

Doylestown, United States

Delaware Crossing Investor Group is a network of former and current executives and entrepreneurs who provide counsel and capital to early-stage and other growth-oriented companies.Delaware Crossing Investor Group is a membership organization of qualified investors who play an active role in the sourcing of prospective portfolio companies,managing the investment process and serving on the board of directors of portfolio companies.

Total investments:
15
Last investment:
Lead investor:
0%

Last updated:

Industries Delaware Crossing Investor Group invests in

Health CareBiotechnologyManufacturingSoftwareTherapeutics

Stages Delaware Crossing Investor Group invests in

SeedSeries AFunding RoundPre-SeedConvertible Note

Countries Delaware Crossing Investor Group invests in

United States

Contacts

NameEmailPhoneSocials
Antonio Tedesco Antonio Tedesco
Michael Murphy Michael Murphy
Richard Woodbridge Richard Woodbridge
Cristian A. Ossa Cristian A. Ossa
Dave Wurz Dave Wurz

Sign up to unlock verified contacts

Unlock Contacts

Investment Focus

Industry

  • Health Care 4 (27%)
  • Biotechnology 4 (27%)
  • Manufacturing 3 (20%)
  • Software 2 (13%)
  • Therapeutics 2 (13%)
See all 35 industries →

Stage

  • Seed 7 (47%)
  • Series A 3 (20%)
  • Funding Round 2 (13%)
  • Pre-Seed 1 (7%)
  • Convertible Note 1 (7%)
See all 6 stages →

Team

NameTitleInvestmentsLinksEmail
Antonio Tedesco
Antonio Tedesco Partner
Partner Total investments: 0
Find email
Michael Murphy
Michael Murphy Member
Member Total investments: 0
Find email
Richard Woodbridge
Richard Woodbridge Member
Member Total investments: 0 Find email
Cristian A. Ossa
Cristian A. Ossa Member
Member Total investments: 0
Find email
Dave Wurz
Dave Wurz Member
Member Total investments: 0
Find email
See all 18 team members →

Investments

CompanyDescriptionRoundLinks
Vytala Vytala
Vytala is a food tech firm focused on improving nutrition through innovative solutions. Pre-Seed / Sep 19, 2024
Measure Studio Measure Studio
Measure Studio is an engine designed to create a social media content strategy that is informed by data. Digital publishers, companies, agencies, and influencers may consolidate and analyze their social media data using the company's engine in order to create better content. The engine offers a safe environment for managing social mediaanalytics. Seed / Apr 21, 2023
SunRay Scientific Inc. SunRay Scientific Inc.
SunRay Scientific (SRS) is a supplier of advanced materials for printed electronics manufacturing and lead free packaging. The company’s key focus is the advancement of green electronics with clean chemistry, which includes development of conductive inks, epoxies and anisotropic conductive adhesives that minimize waste, eliminate use of lead, andreduce carbon footprint in electronics manufacturing. $2.5M / Venture - Series Unknown / Sep 06, 2022
Vesteck Inc. Vesteck Inc.
VESTECK, Inc. (WWW.VESTECK.com) is an early-stage medical device company focused on bringing their proprietary technology to the aortic repair, structural heart and GI markets. Their first product, the "Suture-Tight" nitinol suture delivery catheter will bring a novel technology to endovascular aortic repair market solving a significantglobal challenge for physicians and patients. $4.3M / Series A / Aug 25, 2021
Ophidion Ophidion
Ophidion is a biotechnology company that delivers a central nervous system therapeutics to targeted sites in the brain. The company uses a Trojan horse strategy to exploit an endogenous receptor-mediated transport system to deliver small molecule drugs and biologics into the brain. They are currently focused on developing a pipeline to delivergene-silencing therapies to treat neurodegenerative diseases, including diseases of Cognitive Impairment (e.g. Alzheimer’s disease, Parkinson’s disease) as well as Huntington’s disease.Ophidion platform technology is amenable to delivering multiple classes of drugs, including small molecules and macromolecules (gene therapeutics, siRNA’s, antibodies, peptides, and other macromolecules). It also has an advanced program that is positioned to start pivotal clinical trials to treat anxiety-related disorders, together with a patented companion biomarker diagnostic to select the appropriate patient population. $1.7M / Seed / Oct 03, 2019
ThruPore Technologies ThruPore Technologies
ThruPore Technologies' makes heterogeneous catalysts in pellets and powders. The company provides superior heterogeneous catalysts, initially for reactions using palladium on carbon. $540K / Seed / Feb 21, 2018
Tobly Tobly
Tobly is a B2B equipment rental marketplace built for multi-site facilities managers. $497K / Convertible Note / Jul 20, 2017
OnlySky OnlySky
Only Sky provides a white-label, customizable platform where ski area guests craft their ideal experience on the ski area's website. Ski area staff can manage all inventory, eCommerce, POS commerce, ski school, and events from the same platform. No upfront fees and great ease of use make it an obvious choice for independent ski areas in NorthAmerica, and snow schools around the world. $340K / Seed / Jun 07, 2017
Life.io Life.io
Life.io is the world’s first web-based platform specifically designed to help people make better decisions every moment, to take care of themselves more, to engage more, to simply live more. Delivered through insurance companies or employers, it’s always on, sharing inspired ideas on how to live better today and every day after. $1.5M / Seed / Jan 12, 2016
Annovis Bio Annovis Bio
Annovis Bio is specialty pharmaceutical company founded to develop novel treatments for Alzheimer’s disease (AD), Parkinson’s disease (PD) and other neurodegenerative disorders. The company has two compounds in clinical development: Posiphen® targets early stage AD and PD and may stop or slow the progression of the disease; BNC targets late stageAD and may stabilize the decline. $5.7M / Series A / May 26, 2015
See all 15 investments →

Co-Investors

Access 48,091 investors

822 industries, 177 countries. Updated daily. Emails and phones included.

Browse database — It's Free!

Find investors for your startup

Search 48,091 investors by industry and country. Emails and phones included.

Any industry
Google
Clean Energy
EdTech
Artificial Intelligence
Local
Enterprise Software
Travel
Platforms
InsurTech
Oil and Gas
Social Impact
Retail
Cryptocurrency
SaaS
Film
Restaurants
Photography
Payments
Email
CleanTech
Energy
Marketplace
Fitness
Organic Food
Machine Learning
Health Care
Agriculture (AgTech)
Gaming
Facebook
Social Network
Blockchain
B2B
Video Games
Big Data
Medical Device
Wellness
Mobile
Education
Automotive
Hospitality
Biotechnology
Sports
Consumer
Legal
eSports
Construction
Software
Renewable Energy
Crowdfunding
Venture Capital
Fashion
Social
Theatre
Beauty
Medical
Infrastructure
Recruiting
Cannabis
LGBT
Celebrity
Climate
Web3
Mobile Apps
Life Science
Wine and Spirits
Music
Food and Beverage
Publishing
Art
Manufacturing
Digital Media
FinTech
Finance
Financial Services
Real Estate
Social Media
Franchise
Mobile Advertising
Sporting Goods
Non Profit
Android
Internet
Sustainability
Hardware
Biotech
Impact
Enterprise
Proptech
Transportation
Community
Media (Entertainment)
Any country
Hong Kong
Thailand
United Arab Emirates
Egypt
Greece
Croatia
Burkina Faso
South Korea
Singapore
Gibraltar
Liberia
Taiwan
Tunisia
Sweden
Zimbabwe
Zambia
Norway
Tajikistan
Mexico
Nigeria
Russian Federation
Togo
Guinea
Nepal
Iran
Isle of Man
Madagascar
Pakistan
Romania
Brazil
Kyrgyzstan
LATAM
Africa
Oceania
Oman
Poland
Puerto Rico
Sudan
Cameroon
Guernsey
Andorra
Colombia
Armenia
China
Costa Rica
Czech Republic
Kenya
Kuwait
Marshall Islands
Luxembourg
Malta
Mozambique
Namibia
Mauritius
Nicaragua
Panama
Serbia
Uzbekistan
New Zealand
Australia
Saudi Arabia
Sri Lanka
Jamaica
Switzerland
Guatemala
Kazakhstan
Cayman Islands
Venezuela
Malawi
Myanmar
Uganda
Turkey
Uruguay
Moldova
Morocco
Seychelles
Paraguay
Botswana
Ireland
Japan
South Africa
France
Georgia
Denmark
Ghana
Iraq
Mali
Latvia
Malaysia
Portugal
Philippines
Sierra Leone
Rwanda
El Salvador
Senegal
Tanzania
Germany
India
United States
Indonesia
Middle East
Dominican Republic
Bermuda
Asia
Albania
Spain
Angola
Europe
Cyprus
Qatar
Argentina
Bangladesh
Belgium
Barbados
Jordan
Austria
Ethiopia
Azerbaijan
Bulgaria
Ecuador
Bahamas
Faroe Islands
Estonia
Jersey
Bahrain
Canada
Bolivia
Algeria
Belize
Finland
Italy
Belarus
Hungary
Grenada
Israel
United Kingdom
Iceland
Cambodia
Honduras
Lithuania
Liechtenstein
Lebanon
Mongolia
Peru
Slovenia
San Marino
Ukraine
Vietnam
Chile
Angel Investors
VC Funds
All Investors

Similar Investors

Recommended lists

FAQ

What does Delaware Crossing Investor Group invest in?

Delaware Crossing Investor Group invests primarily in Health Care, Biotechnology and Manufacturing startups, most often at Seed and Series A stage. Most of the 15 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.

How do I contact Delaware Crossing Investor Group?

Public channels for Delaware Crossing Investor Group include LinkedIn and the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.

Who are the partners at Delaware Crossing Investor Group?

The team at Delaware Crossing Investor Group includes Antonio Tedesco (Partner), Michael Murphy (Member) and Richard Woodbridge (Member), among 18 team members tracked by Shizune. The Team section lists each member with their title, investment count and links.

Is Shizune's investor data accurate?

Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.

Contact your first 100 investors today

Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.

Find investors — It's Free!
Delaware Crossing Investor Group Delaware Crossing Investor Group Find emails